ArticleTrials2026

Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial.

Olivier Brugière et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.